CG Oncology Inc. (NASDAQ: CGON) Stock Information | RedChip

CG Oncology Inc. (NASDAQ: CGON) Listen to this Section


$34.26
-0.1400 ( -0.41% ) 468.5K

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Market Data


Open


$34.26

Previous close


$34.40

Volume


468.5K

Market cap


$2.30B

Day range


$33.82 - $35.02

52 week range


$25.77 - $50.23

Insider Ownership Transactions

Total Amount Purchased: 3,389,364.00 | $ 116,119,610.64

Date Type Amount Purchased Purchaser
2024-05-16 Sale -100000.00 Patterson Joshua F.
2024-01-31 Buy 350771.00 Song Hong Fang
2024-01-31 Buy 2000.00 Roche Corleen M.
2024-01-31 Buy 1315.00 Kasturi Vijay
2024-01-31 Buy 3628198.00 Decheng Capital Global Life Sciences Fund IV, L.P.
2024-01-26 Sale -492920.00 Roche Corleen M.

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 13 Aug 08, 2024
10-q Quarterly Reports 63 Aug 08, 2024
8-k 8K-related 13 May 24, 2024
4 Insider transactions 1 May 16, 2024
3 Insider transactions 2 May 16, 2024
10-q Quarterly Reports 63 May 09, 2024
8-k 8K-related 15 May 09, 2024
8-k 8K-related 13 May 03, 2024
4/a Other 1 Apr 09, 2024
10-k Annual reports 19 Mar 26, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.